Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer.

INTRODUCTION: This multicenter phase II study determined the efficacy and safety of new daily oral S-1 and weekly irinotecan (CPT-11) combination schedule in patients with previously untreated advanced or recurrent colorectal cancer. PATIENTS AND METHODS: Patients received first-line chemotherapy comprising S-1 80 mg/m(2)/day given on days 3 to 7, 10 to 14, and 17 to 21 and 60 mg/m(2) CPT-11 administered intravenously on days 1, 8, and 15 of a 28-day cycle. RESULTS: A total of 45 eligible patients were enrolled in this study. The overall response rate was 48.9%. Median progression-free survival and median overall survival was 8.1 months and 20.9 months, respectively. The rates of grade 3 or 4 toxicity were as follows: neutropenia, 8.9%; anemia, 4.4%; anorexia, 6.7%; and diarrhea, 6.7%. CONCLUSIONS: This new S-1 and irinotecan combination schedule appeared to be an effective, well-tolerated, and convenient regimen in patients with advanced colorectal cancer as compared with conventional regimens such as FOLFIRI and IRIS.

Angiosarcoma of the breast with silicone granuloma: a case report.

Angiosarcoma of the breast is a rare non-epithelial tumor and that accounts for less than 0.1% of primary malignancies of the breast. The disease has a relatively higher occurrence among young people, and its prognosis (3-year-survival of only 38%) is extremely poor compared to breast cancer. Here we present a case of an 87-year-old woman who had undergone bilateral breast augmentation with silicone injections in her youth. Although she became aware of a tumor in her right breast, she waited 8 years before seeking treatment. She felt the tumor growing and experienced swelling and pain, but she ended up declining therapy at that time. Two years later she was brought to our hospital by ambulance for continuous bleeding from the same tumor of the breast, which by that time was over 11 cm in diameter. We performed emergency mastectomy. The histological diagnosis was angiosarcoma of the breast with silicone granuloma.

Computed tomographic features of bilateral coronoid process hyperplasia with special emphasis on patients without interference between the process and the zygomatic bone.

OBJECTIVE: To reveal computed tomography (CT) features of patients with coronoid process hyperplasia without interference between the process and the zygomatic bone. STUDY DESIGN: A case-control study was designed. Thirteen cases without interference (2 male and 11 female, 28-56 years old) and 65 controls were sampled from a patient database. Differences in CT features were analyzed between the 2 groups regarding the following 7 points of 5 regions: configuration of the coronoid process, vertical level of the coronoid process, the distance between the bilateral zygomatic arches, thickness of the temporal muscle, anteroposterior width of the temporal muscle, thickness of the temporal muscle tendon, and thickness of the masseter muscle. Cluster analysis was applied to differentiate between individuals. RESULTS: All cases had bilateral hyperplastic change of the coronoid process. Differences were found between the cases and controls in 6 of 7 CT features with the exception of temporal muscle thickness. All incidences of significant difference showed larger values in the cases. All cases were clustered into the same group and were differentiated from the controls. CONCLUSION: CT features appeared to be effective for diagnosis of this condition, and these patients should be put into the same category under the diagnosis of coronoid process hyperplasia.